Life Sciences Workshop: Trends in Pharmaceutical and Biotech Patent Law

Patent practice in the life sciences continues to evolve and change. In particular, the FDA has recently issued new rules that will significantly affect Hatch-Waxman litigation. We will discuss these new rules and suggest ways to best position companies in light of the changed rules. Similarly, we will discuss a recently concluded Hatch-Waxman case in the district of Delaware concerning Savella® milnacipran for the treatment of fibromyalgia, emphasizing ways to avoid the various issues that came up during litigation.

Finally, the differing views concerning obviousness came to a head in the Federal Circuit’s en banc decision in Apple v. Samsung. While not a life science case, this decision showcases the various views on obviousness held by different judges on the Federal Circuit and demonstrates the continued uncertainty in this critically important area of the law. Please join us as we address these issues and provide insight to help guide your practice.

Speakers: 
M. Paul Barker 
Howard W. Levine 
Jeffrey D. Smyth 
Cora R. Holt

Program Date & Location:

Tuesday, December 6, 2016
Palo Alto, CA 

Agenda:

11:00 – 11:15 a.m. 
Registration

11:15 a.m. – 4:30 p.m. 
Workshop and Lunch

4:30 – 5:30 p.m. 
Reception

MCLE Credit:

Finnegan confirms that this activity has been certified for 4.5 hours of California MCLE.

There is no charge to attend. For more information, please contact Finnegan IP Programs.